Skip to main content
Kaichi Nishiwaki on Muck Rack

Kaichi Nishiwaki

As seen in: Nature, Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kaichi

Contact Kaichi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial

|
By Hiroshi Ureshino, Kazunori Murai, Takashi Kumagai, Kaichi Nishiwaki, Satoshi Wakita, Chikashi Yoshida, Nobuhiko Uoshima, Junya Kuroda, Takeshi Kondo, Masahiro Chiba, Takuya Miyazaki, Tomoaki Ueda, Takaaki Ono, Kensuke Usuki, Katsumichi Fujimaki, Takayuki Ikezoe, Atsushi Kawaguchi, Shinya Kimura, Tatsuji Mino, Tomoharu Takeoka, Masayuki Mita, Toshihiro Fukushima, Katsuhiro Io, Takahiro Yamauchi
| Nature Verified
To the Editor BCR::ABL1 tyrosine kinase inhibitors (TKIs) have significantly improved the survival outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) [1]. Older patients account for a substantial proportion of the CML population, with >20% of the patients diagnosed at ≥70 years of age.
Open in Who Shared Issue with article?
See all 1 articles